Literature DB >> 23567819

The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA.

Benjamin P Howden1, Anton Y Peleg2, Timothy P Stinear3.   

Abstract

Resistance to new antimicrobials is generally recognized in Staphylococcus aureus soon after they are released for clinical use. In the case of vancomycin, which was first released in the 1950s, resistance was not reported until the mid 1990s, with the description of vancomycin-intermediate S. aureus (VISA), and heterogenous-VISA (hVISA). Unraveling the complex genetic and cell wall structural changes conferring low-level vancomycin resistance in S. aureus has proved challenging. However the recent advances in high throughput whole-genome sequencing has played a key role in determining the breadth of bacterial chromosomal changes linked with resistance. Diverse mutations in a small number of staphylococcal regulatory genes, in particular walKR, graRS, vraSR and rpoB, have been associated with hVISA and VISA. Only a small number of these mutations have been experimentally proven to confer the resistance phenotype and some of these only partially contribute to resistance. It also appears that the evolution of VISA from VSSA is a step-wise process. Transcriptomics studies, and analysis of host pathogen interactions, indicate that the evolution of vancomycin-susceptible S. aureus to VISA is associated not only with antibiotic resistance, but with other changes likely to promote persistent infection. These include predicted alterations in central metabolism, altered expression of virulence associated factors, attenuated virulence in vivo, and alterations in susceptibility to host innate immune responses, together with reduced susceptibility to other antibiotics. In fact, current data suggests that hVISA and VISA represent a bacterial evolutionary state favoring persistence in the face of not only antibiotics, but also the host environment. The additional knowledge of staphylococcal biology that has been uncovered during the study of hVISA and VISA is significant. The present review will detail the current understanding of the evolutionary process in the generation of hVISA and VISA, and explore the diverse additional changes that occur in these strains.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Evolution; Staphylococcus aureus; VISA; Vancomycin resistance; hVISA

Mesh:

Substances:

Year:  2013        PMID: 23567819     DOI: 10.1016/j.meegid.2013.03.047

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  43 in total

1.  Antibiotic resistance as collateral damage: the tragedy of the commons in a two-disease setting.

Authors:  Daozhou Gao; Thomas M Lietman; Travis C Porco
Journal:  Math Biosci       Date:  2015-02-26       Impact factor: 2.144

2.  Clinical and microbiologic analysis of the risk factors for mortality in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia.

Authors:  Yong Pil Chong; Ki-Ho Park; Eun Sil Kim; Mi-Na Kim; Sung-Han Kim; Sang-Oh Lee; Sang-Ho Choi; Jin-Yong Jeong; Jun Hee Woo; Yang Soo Kim
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

3.  Reduced Vancomycin Susceptibility of Methicillin-Susceptible Staphylococcus aureus Has No Significant Impact on Mortality but Results in an Increase in Complicated Infection.

Authors:  Sean B Sullivan; Eloise D Austin; Stephania Stump; Barun Mathema; Susan Whittier; Franklin D Lowy; Anne-Catrin Uhlemann
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

Review 4.  Approved Glycopeptide Antibacterial Drugs: Mechanism of Action and Resistance.

Authors:  Daina Zeng; Dmitri Debabov; Theresa L Hartsell; Raul J Cano; Stacy Adams; Jessica A Schuyler; Ronald McMillan; John L Pace
Journal:  Cold Spring Harb Perspect Med       Date:  2016-12-01       Impact factor: 6.915

5.  New Evidence and Insights on Dalbavancin and Wound Healing in a Mouse Model of Skin Infection.

Authors:  Oriana Simonetti; Guendalina Lucarini; Gianluca Morroni; Fiorenza Orlando; Raffaella Lazzarini; Antonio Zizzi; Lucia Brescini; Mauro Provinciali; Andrea Giacometti; Annamaria Offidani; Oscar Cirioni
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

6.  Detection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America.

Authors:  Betsy E Castro; Maritza Berrio; Monica L Vargas; Lina P Carvajal; Lina V Millan; Rafael Rios; Angie K Hernandez; Sandra Rincon; Paola Cubides; Erika Forero; An Dinh; Carlos Seas; Jose M Munita; Cesar A Arias; Jinnethe Reyes; Lorena Diaz
Journal:  J Antimicrob Chemother       Date:  2020-09-01       Impact factor: 5.790

Review 7.  Antimicrobial Resistance in ESKAPE Pathogens.

Authors:  David M P De Oliveira; Brian M Forde; Timothy J Kidd; Patrick N A Harris; Mark A Schembri; Scott A Beatson; David L Paterson; Mark J Walker
Journal:  Clin Microbiol Rev       Date:  2020-05-13       Impact factor: 26.132

8.  Mutations in the primary sigma factor σA and termination factor rho that reduce susceptibility to cell wall antibiotics.

Authors:  Yong Heon Lee; John D Helmann
Journal:  J Bacteriol       Date:  2014-08-11       Impact factor: 3.490

9.  Stepwise decrease in daptomycin susceptibility in clinical Staphylococcus aureus isolates associated with an initial mutation in rpoB and a compensatory inactivation of the clpX gene.

Authors:  Kristoffer T Bæk; Louise Thøgersen; René G Mogenssen; Maiken Mellergaard; Line E Thomsen; Andreas Petersen; Søren Skov; David R Cameron; Anton Y Peleg; Dorte Frees
Journal:  Antimicrob Agents Chemother       Date:  2015-08-31       Impact factor: 5.191

10.  Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model.

Authors:  Jordan R Smith; Anu Arya; Juwon Yim; Katie E Barber; Jessica Hallesy; Nivedita B Singh; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.